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Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
is a highly transmissible coronavirus responsible for the global
COVID-19 pandemic. Herein, we provide evidence that SARS-CoV-2
spreads through cell–cell contact in cultures, mediated by the spike
glycoprotein. SARS-CoV-2 spike is more efﬁcient in facilitating cellto-cell transmission than is SARS-CoV spike, which reﬂects, in part,
their differential cell–cell fusion activity. Interestingly, treatment
of cocultured cells with endosomal entry inhibitors impairs cellto-cell transmission, implicating endosomal membrane fusion as
an underlying mechanism. Compared with cell-free infection, cellto-cell transmission of SARS-CoV-2 is refractory to inhibition by
neutralizing antibody or convalescent sera of COVID-19 patients.
While angiotensin-converting enzyme 2 enhances cell-to-cell transmission, we ﬁnd that it is not absolutely required. Notably, despite
differences in cell-free infectivity, the authentic variants of concern
(VOCs) B.1.1.7 (alpha) and B.1.351 (beta) have similar cell-to-cell
transmission capability. Moreover, B.1.351 is more resistant to neutralization by vaccinee sera in cell-free infection, whereas B.1.1.7 is
more resistant to inhibition by vaccinee sera in cell-to-cell transmission. Overall, our study reveals critical features of SARS-CoV-2 spikemediated cell-to-cell transmission, with important implications for a
better understanding of SARS-CoV-2 spread and pathogenesis.
SARS-CoV-2 j cell-to-cell transmission j cell–cell fusion j neutralization j
variants of concern

transfer of virus to neighboring cells (24). Additionally, cellto-cell transmission has the ability to evade antibody neutralization, accounting for efficient virus spread and pathogenesis, as has
been shown for HIV and hepatitis C virus (HCV) (28–32). Low
levels of neutralizing antibodies, as well as a deficiency in type I
IFNs, have been reported for SARS-CoV-2 (18, 33–37) and
may have contributed to the COVID-19 pandemic and disease
progression (38–43).
In this work, we evaluated cell-to-cell transmission of SARSCoV-2 in the context of cell-free infection and in comparison
with SARS-CoV. Results from this in vitro study reveal the heretofore unrecognized role of cell-to-cell transmission that potentially impacts SARS-CoV-2 spread, pathogenesis, and shielding
from antibodies in vivo.
Results
The Spike Protein of SARS-CoV-2 Efficiently Mediates Cell-to-Cell
Transmission of Lentiviral Pseudotypes. The spike is the only viral

transmembrane protein that directly mediates SARS-CoV-2
entry into host cells. We evaluated whether the spike protein of
SARS-CoV-2 is critical for viral spread through cell–cell contact. In order to compare the efficiency of cell-to-cell vs. cellfree infection mediated by the spike proteins of SARS-CoV-2
and SARS-CoV, we took advantage of an intron-Gaussia
Signiﬁcance
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ARS-CoV-2 is a novel beta-coronavirus that is closely related
to two other highly pathogenic human coronaviruses, SARSCoV and MERS-CoV (1). The spike (S) proteins of SARS-CoV-2
and SARS-CoV mediate entry into target cells, and both use
angiotensin-converting enzyme 2 (ACE2) as the primary receptor (2–6). The spike protein of SARS-CoV-2 is also responsible
for induction of neutralizing antibodies, thus playing a critical
role in host immunity to viral infection (7–10).
Similar to HIV and other class I viral fusion proteins, SARSCoV-2 spike is synthesized as a precursor that is subsequently
cleaved and highly glycosylated; these properties are critical for
regulating viral fusion activation, native spike structure, and evasion of host immunity (11–15). However, distinct from SARSCoV, yet similar to MERS-CoV, the spike protein of SARS-CoV-2
is cleaved by furin into S1 and S2 subunits during the maturation
process in producer cells (6, 16, 17). S1 is responsible for binding
to the ACE2 receptor, whereas S2 mediates viral membrane
fusion (18, 19). SARS-CoV-2 spike can also be cleaved by additional host proteases, including transmembrane serine protease 2
(TMPRSS2) on the plasma membrane and several cathepsins in
the endosome, which facilitate viral membrane fusion and entry
into host cells (20–22).
Enveloped viruses spread in cultured cells and tissues via two
routes: by cell-free particles and through cell–cell contact (23–26).
The latter mode of viral transmission normally involves tight
cell–cell contacts, sometimes forming virological synapses, where
local viral particle density increases (27), resulting in efficient
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It is currently unknown if SARS-CoV-2 can spread through
cell–cell contacts, and if so, the underlying mechanisms and
implications. In this work, we show, by using lentiviral
pseudotyped virus, that the spike protein of SARS-CoV-2
mediates the viral cell-to-cell transmission, with an efﬁciency higher than that of SARS-CoV. We also ﬁnd that
cell–cell fusion contributes to cell-to-cell transmission, yet
ACE2 is not absolutely required. While the authentic variants
of concern (VOCs) B.1.1.7 (alpha) and B.1.351 (beta) differ in
cell-free infectivity from wild type and from each other, these
VOCs have similar cell-to-cell transmission capability and
exhibit differential sensitivity to neutralization by vaccinee
sera. Results from our study will contribute to a better understanding of SARS-CoV-2 spread and pathogenesis.
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Fig. 1. The spike protein of SARS-CoV-2 and SARS-CoV mediates cell-to-cell transmission of HIV-1 lentiviral pseudotypes. (A and B) Schematic representations of cell-to-cell and cell-free infection assays (see details in Materials and Methods). Brieﬂy, the inGluc-based lentiviral pseudotypes bearing spike were
produced in 293T cells, which were cocultured with the target cells (293T/ACE2) for cell-to-cell transmission; the Gluc activity of cocultured cells was measured over time (A). Cell-free infection was performed by harvesting virus from the same number of producer cells, followed by infecting 293T/ACE2 target
cells in the presence of the same number of untransfected 293T cells; alternatively, cell-free infection was carried out in Transwell plates, from which Gluc
activity was measured (B). (C) Comparison of cell-to-cell transmission mediated by SARS-CoV-2 or SARS-CoV spike. Results shown were from six independent
experiments, with cell-free infection measured at 48 and 72 h after coculture; the portion of cell-free infection was excluded (n = 6). (D) Comparison of cellfree infection mediated by SARS-CoV-2 or SARS-CoV spike. Results were from six independent experiments (n = 6). (E) The expression level of spike proteins
on the plasma membrane of donor cells was measured by ﬂow cytometry using a polycolonal antibody T62, which detects both SARS-CoV-2 and SARS-CoV.
(F and G) The calculated ratios between cell-to-cell and cell-free infection mediated by SARS-CoV-2 or SARS-CoV-2 spike. Results from cell coculture are
shown in F and from Transwell plates shown in G (n = ∼3 to 6). PV, pseudotyped virus. *P < 0.05, **P < 0.01 . ns, not signiﬁcant.

luciferase (inGluc) HIV-1 lentiviral vector bearing the spike
of interest. In this system, the cells producing the inGluc lentiviral virions bearing the spike protein cannot themselves express
Gluc because the intron is only removed during splicing of the
virion genome transcribed from the integrated genome and not
during the production of Gluc mRNA. However, when that lentivirus pseudotype enters a target cell, that genome is reverse transcribed and integrated into a new cell, and the cytomegalovirus
promotor drives transcription of the now intron-less Gluc transcript leading to Gluc protein production (44, 45). We measured
Gluc activity as a readout to compare the cell-to-cell and cell-free
infection efficiencies (Fig. 1 A and B and Materials and Methods).
Because cell-contact–mediated infection comprises both cell-tocell transmission and cell-free infection, we calculated the efficiency of cell-to-cell transmission by subtracting the portion of
cell-free infection performed in parallel (Materials and Methods).
Despite ∼2-fold lower level of SARS-CoV-2 cell-to-cell transmission compared with SARS-CoV after 48 h of coculturing
of spike-bearing inGluc lentiviral pseudotype producer cells
and 293T cells stably expressing human ACE2 (293T/ACE2),
we observed similar levels of cell-to-cell transmission between
SARS-CoV-2 and SARS-CoV by 72 h, indicating a more efficient
spread of SARS-CoV-2 (Fig. 1C). In contrast, the rate of cell-free
infection of SARS-CoV was much higher than that of SARSCoV-2, i.e., ∼10-fold, as measured at 48 and 72 h postinfection
(Fig. 1D). Flow cytometric analysis of viral producer cells using a
polyclonal antibody that recognizes the S1 of both SARS-CoV-2
2 of 12 j PNAS
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and SARS-CoV spikes showed that the fluorescence signal of
SARS-CoV spike was higher than that of SARS-CoV-2 (Fig. 1E),
in agreement with our previous report (46). By averaging results
from six independent experiments, we estimated that cell-to-cell
transmission contributed to >90% of the total SARS-CoV-2
spread in the coculturing system, as compared with ∼60% for
SARS-CoV performed in identical experimental settings (Fig. 1F).
Parallel experiments were also performed by using a Transwell
system, which showed ∼90% cell-to-cell vs. ∼10% cell-free infection for SARS-CoV-2 compared with ∼77% cell-to-cell vs. ∼23%
cell-free for SARS-CoV (Fig. 1G). Collectively, these results
revealed that the spike protein of SARS-CoV-2 mediates cellto-cell transmission of lentiviral pseudotypes more efficiently than
the spike protein of SARS-CoV. However, the SARS-CoV spike
is more capable of mediating cell-free infection compared with
SARS-CoV-2 in the lentiviral pseudotyping system.
Recombinant Vesicular Stomatitis Virus (rVSV) Expressing SARSCoV-2 Spike Spreads Faster than rVSV Bearing SARS-CoV Spike. We

next compared the spreading infection of replication-competent
rVSV expressing SARS-CoV-2 or SARS-CoV spike. This system
has been previously used to study the cell-to-cell transmission of
Ebolavirus (EBOV) mediated by the glycoprotein (GP) (30). Vero
cells were inoculated with a relatively low multiplicity of infection (MOI) (0.01) of rVSV expressing GFP and SARS-CoV-2
spike in the place of VSV G protein (rVSV-GFP-SARS-CoV-2)
or SARS-CoV spike (rVSV-GFP-SARS-CoV) (47). Cells were
Zeng et al.
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Fig. 2. rVSV expressing SARS-CoV-2 spike spreads faster than does rVSV bearing SARS-CoV spike. Vero-E6 cells were infected with rVSV-GFP-SARS-CoV-2
or SARS-CoV (MOI = 0.01); 1 h postinfection, cells were washed with PBS and cultured in the presence of 1% methylcellulose. Photos were taken at 18
h and 24 h (A). After 72 h of infection, cells were ﬁxed with 3.7% paraformaldehyde (PFA) and stained with crystal violet (B). The number and size of plaques are plotted in C and D, respectively. ***P < 0.001. ns, not signiﬁcant.

overlaid with 1% methylcellulose to block viral diffusion, and
the number and size of GFP-positive plaques were stained and
determined by fluorescence microscopy. Despite similar numbers of GFP-positive plaques between SARS-CoV-2 and SARSCoV, which confirmed equivalent inoculations, the sizes for
SARS-CoV-2 plaques were noticeably larger, as inspected at
18 and 24 h postinfection (Fig. 2 A and B). Quantitative analyses of data at 72 h showed that the size of SARS-CoV-2
plaques (diameter 0.93 ± 0.03 mm) was about two times greater
than that of SARS-CoV (diameter 0.53 ± 0.02 mm), whereas the
plaque numbers between SARS-CoV-2 and SARS-CoV were
comparable (Fig. 2 C and D).
We next attempted to visualize cell-to-cell transmission of
rVSV-GFP-SARS-CoV-2 by imaging fluorescent dye transfer
in cocultured cells, either in the presence of methylcellulose
or monoclonal antibody 2B04 against the SARS-CoV-2 spike.
In this experiment, donor Vero cells were infected with rVSVGFP-SARS-CoV-2 at different MOIs and subsequently cocultured
with target Vero cells stably expressing mTomato (Vero-mTomatoRed). Efficient transmission was detected using fluorescence
microscopy, as well as by flow cytometry at 6 h, with 23.9%
double-positive cell populations (SI Appendix, Fig. S1 A and B).
Treating cocultured cells with methylcellulose, which has been
found to prevent cell-free infection by drastically reducing the
diffusion of virions between cells (24), or 2B04 that potently
inhibits cell-free infection (46), reduced the cell-to-cell transmission to 12.7% and 5.38%, respectively. Combining results from
multiple independent experiments, we estimated that ∼50% of
the total infection came from cell-to-cell transmission, which was
Zeng et al.
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still partially blocked by 2B04 (SI Appendix, Fig. S1C). Similar
experiments performed in parallel for rVSV-GFP-SARS-CoV
showed a stronger inhibition by methylcellulose (∼65%), suggesting a more efficient cell-free infection of rVSV-GFP-SARS-CoV
compared with that of SARS-CoV-2. Importantly, 2B04 had no
effect on cell-to-cell or cell-free infection of rVSV-GFP-SARSCoV as would be expected since 2B04 does not cross-react with
SARS-CoV (SI Appendix, Fig. S1 D–F) (46, 48). Altogether, these
results demonstrated that, similar to lentiviral pseudotypes, the
spike protein of SARS-CoV-2 more efficiently mediates the cellto-cell transmission of rVSV-GFP than SARS-CoV.
The Higher Cell–Cell Fusion Activity of SARS-CoV-2 Spike Contributes
to Efficient Cell-to-Cell Transmission of the Pseudotyped Virus. We

next explored whether cell–cell fusion by SARS-CoV-2 spike plays
a role in cell-to-cell transmission. To this end, we cotransfected
293T cells with plasmids expressing the inGluc lentiviral vector,
SARS-CoV-2 or SARS-CoV spike, and GFP. The transfected producer cells were cocultured with target 293T/ACE2 cells; syncytia
formation and cell-to-cell transmission were measured over time.
Following ∼2 h of coculturing, we observed small but apparent
syncytia for SARS-CoV-2, yet with no syncytia formation for
SARS-CoV (Fig. 3A). At 24 h following coculturing, more syncytia formation, with larger sizes, was observed in cells expressing
SARS-CoV-2 spike, whereas fewer and smaller syncytia were seen
for SARS-CoV (Fig. 3A). The difference between SARS-CoV-2
and SARS-CoV spike-induced cell–cell fusion was further evaluated by a more quantitative, Tet-off–based fusion assay, which
PNAS j 3 of 12
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EK1 inhibited the ability of SARS-CoV spike to induce small
syncytia, we did not find obvious inhibition of EK1 on SARSCoV spike-mediated cell-to-cell transmission (Fig. 3 C and D).
To investigate whether these results were cell-type dependent, we
performed similar experiments using human intestine epithelial
Caco-2 as target cells and found that EK1 indeed inhibited the
cell-to-cell transmission of both SARS-CoV-2 and SARS-CoV
(Fig. 3E). Overall, these results support the concept that the
cell–cell fusion activity of SARS-CoV-2 and SARS-CoV spike
contributes to cell-to-cell transmission, in a cell type–dependent
manner, and that extensive syncytia formation could lead to cell
death and therefore decreased transmission efficiency at the late
stage of the processes.
ACE2 Enhances but Is Not Required for Cell-to-Cell Transmission.
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Fig. 3. Cell–cell fusion mediated by SARS-CoV and SARS-CoV-2 spike contributes to cell-to-cell transmission. (A) Syncytia formation mediated by the spike
of SARS-CoV-2 or SARS-CoV. The 293T donor cells were cotransfected with
plasmids encoding SARS-CoV-2 or SARS-CoV spike, lentiviral NL4-3 inGluc vector, and eGFP. After 24 h posttransfection, the donor cells were cocultured
with target 293T/ACE2 cells at a 1:1 ratio, with fusion monitored over time
and photos taken after 2 h and 24 h, respectively. (B) Quantiﬁcation of
cell–cell fusion. The 293T cells were transfected with plasmids encoding
tet-off or SARS-CoV or SARS-CoV-2 spike and cocultured with target 293FTmCAT-Gluc cells, which were transfected with a plasmid expressing ACE2;
Gluc activity was measured from the supernatant of cocultured cells at 24 h
and 48 h, respectively. Relative fusion was plotted by setting the fusion
activity of SARS-CoV as 1.0. (C–E) Fusion inhibitor EK1 inhibits cell–cell
fusion of SARS-CoV-2 spike, in accordance with its effect on cell-to-cell
transmission. Effect of EK1 on syncytia formation induced by SARS-CoV-2
spike (C); photos were taken at 24 h. Effects of EK1 on SARS-CoV-2 or SARS-CoV
infection from 293T to 293T/ACE2 (D) or from 293T to Caco-2 (E). Transfected
293T donor cells were cocultured with 293T/ACE2 or Caco-2 cells in the
presence or absence of 10 μM EK1, and Gluc activity was measured at
24 to 72 h after coculture. Results from three to six independent experiments were averaged and plotted as relative values by setting the mock
control as 100% (n = ∼3 to 6). PV, pseudotyped virus. ***P < 0.001. ns, not
signiﬁcant.

showed an approximately fivefold higher fusion activity of SARSCoV-2 compared with that of SARS-CoV (Fig. 3B).
We next treated cocultured cells with a pan-coronavirus fusion
peptide inhibitor EK1 that has been shown to inhibit fusion of
SARS-CoV-2, SARS-CoV, and other related CoVs (49, 50), and
simultaneously measured its effect on cell–cell fusion and cellto-cell transmission. Syncytia formation of SARS-CoV-2 was
strongly inhibited by EK1 (Fig. 3C), in accordance with its effect
on cell-to-cell transmission (Fig. 3D). Unexpectedly, although
4 of 12 j PNAS
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ACE2 is the primary receptor of both SARS-CoV-2 and SARSCoV, mediating viral entry into host cells. We next evaluated the
role of ACE2 in cell-to-cell transmission as compared with cellfree infection. We observed increased cell-to-cell and cell-free
infection when more plasmid encoding ACE2 was transfected
into the target 293T cells, as would be expected (Fig. 4 A and B).
Interestingly, with a relatively low dose of ACE2 (i.e., 0.2 μg),
SARS-CoV-2 reached ∼70% of its maximal cell-to-cell transmission (at 0.5 μg ACE2). In contrast, SARS-CoV showed ∼30%
maximal cell-to-cell transmission at 1.5 μg ACE2 (Fig. 4 A and B).
Notably, when the highest dose of ACE2 (1.5 μg) was transfected into target cells, we consistently observed decreased
cell-to-cell transmission of SARS-CoV-2 compared with a continually increasing trend for SARS-CoV (Fig. 4 A and B). This pattern of cell-to-cell transmission was different from that of cell-free
infection, where both SARS-CoV-2 and SARS-CoV exhibited an
increase, with similar kinetics, in a strictly ACE2 dose–dependent
manner (Fig. 4 A and B). We confirmed ACE2 expression in
target cells by flow cytometry and Western blotting (SI Appendix,
Fig. S2 A and B). Consistent with increasing expression of ACE2
in target cells, we observed increasing sizes of syncytia formation for SARS-CoV-2, but cell–cell fusion by SARS-CoV was
not evident (SI Appendix, Fig. S2C). Giant syncytia formation
at 1.5 μg ACE2 resulted in cell death, which might have contributed to decreased cell-to-cell transmission for SARS-CoV-2
(SI Appendix, Fig. S2C). Overall, these results indicate that
ACE2 enhances cell-to-cell transmission of both SARS-CoV-2
and SARS-CoV in the lentiviral pseudotyping system, yet the
former requires less ACE2 for the process to occur.
We further explored whether cell-to-cell transmission of SARSCoV-2 can occur in the absence of ACE2 expression in target
cells. We first used NCI-H520, a human lung epithelial cell line
that expresses an extremely low level of ACE2 (SI Appendix,
Fig. S2D). Cell-to-cell transmission was detected at day 2, which
continued to increase through day 4. In contrast, cell-free infection was not detected in NCI-H520 cells throughout the 3-d
period (Fig. 4C). Cell-to-cell transmission was also observed for
SARS-CoV in H520 cells, at a higher level than that of SARSCoV-2; but again, similar to SARS-CoV-2, no/low cell-free infection was detectable (Fig. 4D). We next tested human peripheral
blood mononuclear cells (PBMCs), which do not express ACE2
(SI Appendix, Fig. S2D), and observed apparent cell-to-cell transmission for both SARS-CoV and SARS-CoV-2, yet no/low cellfree infection was detected, the latter being consistent with
recently published results (51) (Fig. 4 E and F). As a control, we
carried out cell-to-cell transmission and cell-free infection in
Calu-3, a human lung epithelial cell line that expresses a higher
level of ACE2 (SI Appendix, Fig. S2D). A rapid increase in cell-tocell transmission was observed for SARS-CoV-2 from day 2
through day 4, despite an overall level of infection for SARSCoV that was higher than observed for SARS-CoV-2 (SI
Appendix, Fig. S2 E and F). Together, these results demonstrated that cell-to-cell transmission of lentiviral pseudotypes
Zeng et al.
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Fig. 4. ACE2 enhances cell-to-cell transmission but is not absolutely required. (A and B) Cell-to-cell and cell-free infection were performed as described
for Figs. 1 and 3 except that target cells were 293T transfected with different amounts of a plasmid encoding ACE2. Relative rates of cell-to-cell transmission and cell-free infection were calculated by setting the values of 0.5 μg ACE2 to 1.0 (A and B, n = 3). (C–F) Experiments were carried out as described
for Figs. 1 and 3 except that target cells were H520 and human PBMCs (n = 3 for each). (G) Vero-ACE2-TMPRSS2-mTomato (Red) cells were infected with
MOI = 0.01 of authentic SARS-CoV-2 WT (USA-WA1/2020) for 18 h, followed by coculturing of the donor NCI-H520 cells for another 4 h or 20 h. Cells
were ﬁxed and stained with an anti–SARS-CoV-2 N protein for ﬂow cytometric analysis. The same number of NCI-H520 cells were infected with the WT
SARS-CoV-2 harvested from the SARS-CoV-2–infected donor Vero-ACE2-TMPRSS2-mTomato cells for 4 h or 20 h for cell-free infection and analyzed by
ﬂow cytometry. (H) Results of Q3 quadrant analyses were plotted. ***P < 0.001. PV, pseudotyped virus.

bearing SARS-CoV-2 or SARS-CoV spike can occur in the
absence of ACE2.
We next examined cell-to-cell infection of low-ACE2 H520 cells
using authentic SARS-CoV-2 under biosafety level 3 (BSL3) conditions. We infected Vero-ACE2-TMPRSS2-mTomato cells with
SARS-CoV-2 (USA-WA1/2020), which served as donor cells,
and we cocultured them with H520 target cells for different
Zeng et al.
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periods of time. The cell-to-cell infection efficiency was determined by detecting the SARS-CoV-2 N protein in H520 cells
using flow cytometry. In parallel, the cell-free infection of H520
cells was also analyzed. At 4 and 20 h following coculturing, we
observed that 9.32 to 14.7% of H520 cells became positive for
the SARS-CoV-2 N protein, whereas less than 1% of H520 cells
were positive in cell-free infection (Fig. 4 G and H and SI
PNAS j 5 of 12
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Appendix, Fig. S2G). These results indicated that the authentic
SARS-CoV-2 can infect H520 cells expressing a very low level
of ACE2.
Cell-to-Cell Transmission of SARS-CoV-2 Involves Endosomal Entry.

SARS-CoV-2 uses different pathways for entry, either at the
plasma membrane and/or in the endosomal compartment (20,
52–56). While our results indicated that entry via the plasma
membrane is important for cell-to-cell transmission, we probed
whether fusion in the endosomal compartment may also be
involved. We applied in parallel a panel of endosomal inhibitors
to the cell-to-cell and cell-free infection assays. We found that
cathepsin L inhibitor III, cathepsin B inhibitor CA-074, E-64d
(general cathepsin inhibitor), BafA1 (ATPase pump inhibitor),
and leupeptin (general protease inhibitor), all significantly
inhibited cell-to-cell transmission (Fig. 5A). Interestingly, the
effect of these drugs on SARS-CoV-2 were generally less potent
compared with SARS-CoV, with the exception of cathepsin L
inhibitor III (Fig. 5A). Moreover, these drugs generally showed
a stronger effect on cell-free infection, again especially for
SARS-CoV (Fig. 5B). Of note, CA-074 had modest effects on
both viruses (Fig. 5B), which was consistent with the notion that
cathepsin B does not play a significant role in cleaving the spike
protein of SARS-CoV and SARS-CoV-2, which is required for
fusion (57, 58). We also applied these inhibitors to cell–cell fusion
assays but found no effect on either SARS-CoV-2 or SARS-CoV,
as would be expected (SI Appendix, Fig. S3). To assess possible
cell type–dependent effects, we carried out experiments using
Caco-2 target cells and found that cathepsin L inhibitor III and
BafA1 robustly inhibited cell-to-cell transmission and cell-free
infection of both viruses, in particular SARS-CoV (Fig. 5 C and D).
Overall, these results support the notion that endosomal entry is
involved in cell-to-cell transmission of SARS-CoV-2, and to a
greater extent, SARS-CoV of lentiviral pseudotypes.
We further tested the effects of these inhibitors using authentic SARS-CoV-2. We infected Vero-ACE2-TMPRSS2-mTomato
(Red) cells with SARS-CoV-2 (USA-WA1/2020), which were subsequently cocultured with either Vero-ACE2-TMPRSS2 or Calu-3
target cells in the presence of these inhibitors for 4 h. Flow cytometric analysis was used to detect virus-infected cells with an antiN antibody of SARS-CoV-2. Similar to the results of lentiviral
pseudotypes, much weaker effects were observed for these inhibitors on cell-to-cell spread as compared with cell-free infection
(Fig. 5 E and F and SI Appendix, Fig. S4). Together, these results
suggested that the endosomal entry pathway is involved in cell-tocell transmission of authentic SARS-CoV-2, but it appears to play
a less dominant role compared with cell-free infection.
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Cell-to-Cell Transmission of SARS-CoV-2 Is Refractory to Neutralizing
Antibody and Convalescent Plasma. One important feature of the

virus cell-to-cell transmission is evasion of host immunity, particularly neutralizing antibody-mediated response. We therefore
examined the sensitivity of SARS-CoV-2 spike-mediated cellto-cell transmission to neutralization by a monoclonal antibody
against the receptor-binding domain of the spike, 2B04 (48), as
well as convalescent plasma derived from COVID-19 patients
(46, 59). While 2B04 effectively inhibited cell-free infection of
SARS-CoV-2 in 293T/ACE2 cells by more than 90%, its effect
on cell-to-cell transmission between 293T and 293T/ACE2 was
∼50% (Fig. 6 A and B). As would be expected, 2B04 had no
effect on SARS-CoV, regardless of cell-to-cell transmission or
cell-free infection (Fig. 6 A and B). We also performed cell–cell
fusion in the presence of different concentrations of 2B04, and
we found that the fusion activity of the SARS-CoV-2 spike was
inhibited in a dose-dependent manner (Fig. 6C). We then
tested five serum samples of COVID-19 patients and observed
that, although they potently inhibited the cell-free infection of
SARS-CoV-2 (P < 0.001), they showed variable but no
6 of 12 j PNAS
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significant effect on cell-to-cell transmission of SARS-CoV-2;
the effect of these sera on SARS-CoV infection, either cell-tocell or cell-free, was minimal or modest (Fig. 6 D and E).
Together, these results indicate that cell-to-cell transmission of
SARS-CoV-2 lentiviral pseudotyped virus is mostly refractory
to neutralization by neutralizing antibodies against spike relative to cell-free infection.
Cell-to-Cell Transmission of Authentic SARS-CoV-2 Variants of Concern
and Their Sensitivity to COVID-19 Vaccinee Sera. The D614G muta-

tion in SARS-CoV-2 spike, as well as emerging variants of concern (VOCs) containing D614G and other key spike mutations,
have been reported to enhance viral infectivity, transmissibility,
and resistance to COVID-19 vaccines (60–65). As such, we examined the cell-to-cell transmission capability of authentic SARSCoV-2 wild type (WT) (USA-WA1/2020), D614G variant (B.1.5),
and two VOCs B.1.1.7 (501Y.V1) and B.1.351 (South African,
501Y.V2), in the presence or absence of pooled sera from mRNA
vaccines (three from Moderna and three from Pfizer). Donor
Vero-ACE2 cells were first infected with WT SARS-CoV-2
(MOI = 0.2), D614G (MOI = 0.02), B.1.1.7 (MOI = 0.02), and
B.1.351 (MOI = 0.02), respectively. Note that a 10-fold higher
MOI was used for WT in order to achieve comparable rates of
infection in donor cells between WT and VOCs, given that
D614G-containing variants are known to significantly increase
the viral infectivity (60, 66). Approximately 20 h postinfection,
the culture media of donor cells was harvested, the whole volume
of which was used to infect target Vero-mTomato-Red cells for
6 h in order to determine the viral infectivity. In parallel, the
infected donor Vero-ACE2 cells were digested and cocultured
with the same number of Vero-Tomato-Red cells as was used in
the cell-free infectivity assay, also for 6 h, as a measurement of
cell-to-cell transmission. To determine the sensitivity of cellto-cell transmission vs. cell-free infection to neutralization by
vaccinee sera, we pooled the serum samples of 6 mRNA vaccines, i.e., three from Moderna and three from Pfizer, and added
them to the cultured medium. The efficiency of cell-to-cell transmission and cell-free infectivity was determined by measuring
the percentage of SARS-CoV-2 nucleocapsid (N)-positive VeromTomato-Red cells using flow cytometry. Considering the potential impact of infected donor cells on cell-to-cell transmission, we
normalized the rate of cell-to-cell transmission with the total rate
of virus spread in both SARS-CoV-2–positive Vero-mTomato-Red
cells as well as Vero-ACE2 cells over the entire infection period,
i.e., from the initial infection of donor cells to the end of the coculture (∼26 h).
Representative flow cytometric results and summary analyses
are presented in Fig. 7 and SI Appendix, Fig. S5. Interestingly, even
with a 10-fold higher MOI used for the WT infection of donor
Vero-ACE2 cells relative to other variants, we observed comparable rates of cell-to-cell transmission between WT, D614G, B.1.1.7,
and B.1.351 (Fig. 7 A, Upper and B and SI Appendix, Fig. S5 A
and B). Note that the relative rate of cell-to-cell transmission
shown in Fig. 7B was obtained by dividing the percentage of
SARS-CoV-2–positive Vero-mTomato-Red cells (Q2 in Fig. 7 A,
Upper) by the percentage of total SARS-CoV-2–positive cells
(Q2 plus Q3 in Fig. 7 A, Upper). We noted that the rate of B.1.351
spreading infection in Vero-ACE2 and Vero-mTomato-Red cells
(Q2 plus Q3 in Fig. 7 A, Upper) was the highest, followed by
B.1.1.7 > D614G > WT (Fig. 7C). Consistent with the more efficient replication of B.1.351 in donor Vero-ACE2 cells over the
entire 26-h infection period (Q3 in Fig. 7 A, Upper), we found a
significantly higher cell-free infectivity for B.1.351 produced during the initial 20-h infection relative to WT, D614G, and B.1.1.7
(Fig. 7D, see “no sera”). Overall, these results revealed a strongly
enhanced replication of B.1.351 relative to B.1.1.7, D614G,
and WT, yet a comparable efficiency of cell-to-cell transmission
between WT, D614G, and VOCs.
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Fig. 5. Endosomal entry pathway is involved in cell-to-cell transmission. Effect of endosomal entry inhibitors on cell-to-cell and cell-free infection of
SARS-CoV-2 and SARS-CoV. Experiments were carried out as described in Fig. 1 C and D, except that indicated inhibitors were present during the infection
period. The concentrations of inhibitors used were as follows: 1 μM or 5 μM Cat L inhibitor III, 1 μM or 5 μM CA-074, 10 μM or 30 μM E-64D, 25 nM or 50 nM
BafA1, and 20 μM or 50 μM leupeptin. (A and B) Effect in 293T cells. (C and D) Effect in Caco-2 cells. In all experiments, Gluc activity was measured at 48 and
72 h after infection, and rates of relative infection were plotted by setting the values of mock infection without drugs to 100. Results were from
approximately four to six independent experiments. (E and F) Effect of inhibitor treatments on cell-to-cell and cell-free infection of authentic SARS-CoV-2
(USA-WA1/2020). Note that Vero-ACE2-TMPRSS2-mTomato (Red) cells served as donor cells, and Vero-ACE2-TMPRSS2 cells served as target cells (n = 3).
PV, pseudotyped virus. *P < 0.05, **P < 0.01, ***P < 0.001. ns, not signiﬁcant.

We also assessed the sensitivity of cell-to-cell transmission and
cell-free infection to neutralization by Moderna and Pfizer vaccinee sera. With a relatively low dose of pooled sera being applied,
we observed that the cell-to-cell transmission of WT, D614G,
B.1.1.7, and B.1.351 was virtually resistant to neutralizing antibodies induced by these mRNA vaccines for all viruses, whereas
the cell-free infection of WT, D614G, and B.1.1.7 was strongly
Zeng et al.
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inhibited, with B.1.351 being resistant (Fig. 7 A, Lower and D
and E and SI Appendix, Fig. S5 C and D). By using HIV-inGluc
pseudotyped viruses with serially diluted serum samples from
Moderna and Pfizer vaccines, we were able to obtain and compare the 50% neutralizing titer (NT50) values of each virus in
cell-to-cell transmission vs. cell-free infection. We found that,
overall, mRNA vaccinee sera neutralized cell-to-cell
PNAS j 7 of 12
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Fig. 6. Cell-to-cell transmission of SARS-CoV-2 is refractory to inhibition by neutralizing antibody and COVID-19 convalescent plasma. (A–C) Effects of
SARS-CoV-2 monoclonal antibody 2B04 on cell-to-cell transmission, cell-free infection, and cell–cell fusion mediated by SARS-CoV-2 or SARS-CoV-2 spike.
The experiments were carried out as described in Fig. 1 C and D, except that 0.2 μg/mL or 2 μg/mL 2B04 were included during the infection period. Relative infections were plotted by setting the values of mock infection without 2B04 to100% for statistical analyses (A and B). The photos of syncytia formation were taken at 18 h after coculture and presented (C). (D and E) Effect of COVID-19 sera on cell-to-cell and cell-free infection of SARS-CoV-2 and
SARS-CoV. Experiments were performed as described as above, except ﬁve diluted COVID-19 sera were included during the infection period. Effect on
cell-to-cell (D) and cell-free (E) infection of SARS-CoV or SARS-CoV-2 were summarized and plotted by setting the values of mock infection control to
100% (n = ∼3 to 4). PV, pseudotyped virus. **P < 0.01, ***P < 0.001. ns, not signiﬁcant.

transmission ∼3-fold less efficiently than cell-free infection,
with the notable exception of B.1.351, which showed similar
extents of inhibition for cell-to-cell and cell-free infections (Fig.
7 F and G). Intriguingly, we found that the cell-to-cell transmission of B.1.1.7 was more resistant to neutralization by vaccinee
sera, with ∼4.9-fold lower NT50 than D614G (P < 0.01) and ∼8.
7-fold lower than B.1.351 (P < 0.05) (Fig. 7 F and G). In contrast, the cell-free infection of B.1.351 was more resistant to
neutralization than D614G and B.1.1.7, with 3.6-fold (P < 0.
01) and ∼2.4-fold (P < 0.01) lower NT50, respectively (Fig. 7 F
and G), which was consistent with recent studies (67, 68). In
8 of 12 j PNAS
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aggregate, these results confirmed that cell-to-cell transmission of both authentic and pseudotyped SARS-CoV-2 VOCs is
more refractory to inhibition by neutralizing antibodies
induced by mRNA vaccines as compared with cell-free infection, and more importantly, showed that the cell-to-cell transmission of B.1.1.7 and the cell-free infection of B.1.351, are
most resistant to antibody neutralization. The differential sensitivity of B.1.1.7 and B.1.351 to neutralization by vaccinee
sera in cell-to-cell transmission vs. cell-free infection likely has
important implications for understanding the spread of these
variants and their pathogenesis in patients (see Discussion).
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Fig. 7. Cell-to-cell transmission of SARS-CoV-2 VOCs and sensitivity to neutralization by vaccinee sera. (A–E) The cell-to-cell transmission capability of
authentic SARS-CoV-2 WT, D614G, B.1.1.7, and B.1.351 in the presence or absence of vaccinee sera. Donor Vero-ACE2 cells were infected with WT SARSCoV-2 (MOI = 0.2), D614G (MOI = 0.02), B.1.1.7 (MOI = 0.02), and B.1.351 (MOI = 0.02) for 20 h, followed by coculturing with target Vero-mTomato (Red)
cells in the presence or absence of pooled mRNA vaccinee sera (three from Moderna and three from Pﬁzer) for 6 h. Cells were ﬁxed and stained with
anti–SARS-CoV-2 N protein and analyzed by ﬂow cytometry. Representative ﬂow cytometric analyses of infected cells are shown in A, with the newly
infected target Vero-mTomato (Red) cells (Q2) as indicative of cell-to-cell transmission. The relative cell-to-cell transmission efﬁciency was calculated by
dividing the rate of Vero-mTomato-Red positive cells (Q2) by the rate of total infected donor and target cells (Q2+Q3) (B, n = 3). The MOI-normalized
total viral spread in both donor and target cells (Q2+Q3) is shown in C (n = 3). The supernatant from the initial 20-h infection of donor cells was used to infect
target Vero-mTomato-Red cells for 6 h as the measurement of cell-free viral infectivity, either in the presence or absence of the pooled vaccinee sera, and
infected cells were analyzed by ﬂow cytometry (D) (n = 3). The pooled vaccinee sera were also added to the cocultured Vero-ACE2 and Vero-mTomato-Red
cells as described in A to determine their effect on cell-to-cell transmission (E). (F and G) The calculated NT50 values of vaccine sera against cell-to-cell transmission and cell-free infection of lentiviral pseudotypes bearing individual spike of VOCs. Experimental procedures were the same as described in Fig. 6 D and E,
except that all comparisons were made relative to the D614G variant (n = 6). *P < 0.05, **P < 0.01, ***P < 0.001. ns, not signiﬁcant.

Discussion
Accumulating evidence indicates that viruses, including the highly
pathogenic HIV, HCV, and EBOV, etc., can efficiently spread
through cell-to-cell transmission (23, 29–31, 69–71). Importantly,
cell-to-cell transmission is more efficient than cell-free infection
(31), and roles for this mode of transmission have been demonstrated in vivo for HIV and other viruses (29, 31, 45, 70). Notably,
many plant viruses are known to use cell-to-cell transmission to
spread from epidermal cells and move sequentially into mesophyll, bundle sheath, and phloem parenchyma and companion
cells (72, 73). For coronaviruses, very little is currently known
about their mode of spread between cells or its efficiency compared with cell-free infection. This question is critical, given the
robust replication of SARS-CoV-2 in human lung and other tissues, as well as the rapid spread of SARS-CoV-2, including some
variants of concern, in the human population, leading to the
global pandemic (38, 67, 68, 74, 75). In this work, we addressed
this question using lentiviral pseudotypes, replication-competent
rVSV expressing the spike of SARS-CoV-2 or SARS-CoV, as well
as authentic SARS-CoV-2. We discovered that SARS-CoV-2
spike is more efficient in mediating cell-to-cell transmission than
SARS-CoV spike, yet the spike of SARS-CoV is more capable of
mediating cell-free infection. To our knowledge, this is a direct
Zeng et al.
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comparison of cell-to-cell transmission vs. cell-free infection
between SARS-CoV-2 and SARS-CoV in cultured cells, and the
results provide important insights into two distinct modes of
infection and the host–viral factors that regulate these processes.
We provide evidence that the relatively robust cell-to-cell
infection efficiency of SARS-CoV-2 is in part related to the
higher cell–cell fusion capability of its spike protein compared
with that of SARS-CoV (Fig. 3). Further evidence supporting a
role of cell–cell fusion in transmission of SARS-CoV-2 came
from the application of a membrane fusion inhibitor EK1, which
significantly attenuated cell-to-cell transmission. Indeed, cell–cell
fusion has been recognized as an important mechanism of cellto-cell infection for a number of enveloped viruses, including
herpesviruses, paramyxoviruses, and retroviruses (23). However,
it must be emphasized that extensive cell–cell fusion by SARSCoV-2 spike can lead to giant syncytia formation and cell death,
which in turn reduces cell-to-cell transmission. While we were
able to confirm the cell-to-cell infection of SARS-CoV-2 using
the authentic WA-1 strain, syncytia formation was not evident in
most cases, except when Vero-ACE2-TMPRRS2-mTomato and
Vero-ACE2-TMPRRS2 cells were used as donor and target cells,
respectively, because of the high level expressions of both ACE2
and TMPRSS2. However, syncytia per se shall not account for
PNAS j 9 of 12
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the transfer of SARS-CoV-2 N protein from donor cells to target
cells, because cells were completely digested by trypsin and fused
cells should have been excluded based on the single cell analysis
using forward scatter area (FSC-A)/forward scatter width (FSCW) gating. In this respect, it is worthwhile noting that authentic
SARS-CoV-2 infection can induce giant syncytia in human lung
epithelial H1299-ACE2 cells (76), although the size of syncytia
induced by SARS-CoV-2 can be cell type–dependent (77). Overall, a fine control of the spike-induced cell–cell fusion is important
for efficient cell-to-cell transmission and, therefore, the spreading
infection of SARS-CoV-2.
Another interesting finding in this work is that although
ACE2 enhances cell-to-cell transmission of SARS-CoV-2 and
SARS-CoV, it is not absolutely required. This observation is
supported further by data from H520 cells and human PBMCs,
which express a minimal level of ACE2 if any, yet exhibited
obvious cell-to-cell transmission of lentiviral pseudotyped virus
(Fig. 4). Moreover, we obtained similar results by using authentic SARS-CoV-2 in H520 cells where clear cell-to-cell transmission was observed (Fig. 4). In all cases, cell-free infection of
SARS-CoV-2 was not detected in H520 cells and PBMCs, further supporting these conclusions. The molecular mechanism
underlying cell-to-cell transmission of SARS-CoV-2, including
the possible roles of cellular cofactors and virological synapses,
shall be investigated in future studies.
A surprising result to emerge from our studies was that,
despite the critical role of cell–cell contact and plasma membrane–
mediated fusion, endosomal entry pathways were also involved in
cell-to-cell transmission of SARS-CoV-2 and SARS-CoV (Fig. 5).
This is evidenced by the inhibitory effect of drugs that specifically
target the endosomal entry pathway of these viruses, including
the CatL inhibitor III, which blocks cleavage of the viral glycoprotein, as well as BafA1, which neutralizes endosomal pH.
These results altogether are reminiscent of previous studies from
HIV and EBOV, where the endocytosis and/or protease cleavage
processed are required for cell-to-cell transmission of these enveloped viruses (26, 30, 71, 78, 79). Interestingly, we find that these
inhibitors appear to be less potent for decreasing cell-to-cell
transmission as compared with cell-free infection, including for
authentic SARS-CoV-2 (Fig. 5 and SI Appendix, Fig. S4), and
moreover, their effects on SARS-CoV-2 are weaker than their
effects on SARS-CoV. We also noticed that the cell-free infection
of SARS-CoV-2 in Vero-ACE2-TMPRRS2 cells was still sensitive
to treatment by endosomal inhibitors, similar to a recent report
(80); we reason that this could be associated with the levels of
TMPPRS2 expression on the plasma membrane of target cells
used for infection, as well as viral stocks that contain furindefective mutants generated from Vero cells. These observations
collectively suggest a less dominant role for the endosomal
entry pathway in cell-to-cell transmission of SARS-CoV-2. Highresolution live microscopic imaging would be useful to dissect the
exact role of endosomal vs. plasma membrane entry pathways in
the cell-to-cell transmission of SARS-CoV-2.
In this work, we also tested the effect of remdesivir (RDV), an
FDA-approved drug, on cell-to-cell infection of SARS-CoV-2.
Previously, RDV has been shown to efficiently inhibit the replication of SARS-CoV-2 in Vero (half-maximal inhibitory concentration [IC50] =11.41 μM) and Calu-3 cells (IC50 = 1.1 μM) (81).
Interestingly, we found only a modest effect of RDV on the cellto-cell spread of authentic SARS-CoV-2, i.e., ∼50% inhibition
from Vero-ACE2-TMPRSS2 to Calu-3 cells, even at a concentration of 100 μM (SI Appendix, Fig. S4 D and E). These results may
not be so surprising, given the relatively shorter cococulturing
time as well as the fact that RDV acts to block only the viral
RNA-dependent RNA polymerase (RdRp) of newly transmitted
virus in target cells, rather than the existing virus that was transferred from donor to target cells. Hence, the limited effect of
RDV for cell-to-cell spread of SARS-CoV-2 supports the
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contention that authentic SARS-CoV-2 spreads efficiently
through cell–cell contact.
Cell-to-cell transmission is considered to be an effective means
by which viruses evade host immunity, especially antibody-mediated
responses. We compared the sensitivity of cell-to-cell transmission vs. cell-free infection of SARS-CoV-2 to treatments by
neutralizing monoclonal antibodies and COVID-19 convalescent plasma—both of which have been approved by the FDA
for emergency use. We found that while cell-free infection of
SARS-CoV-2 was almost completely blocked by these treatments, cell-to-cell transmission of SARS-CoV-2 was, to a large
extent, refractory (Figs. 6 and 7). While not statistically significant,
some of the COVID-19 sera (two out of five) even enhanced
cell-to-cell transmission of SARS-CoV-2 (Fig. 6D), although the
underlying mechanisms are currently not known. Interestingly,
despite significant increases in cell-free infectivity, the South
Africa variant B.1.351, the UK variant B.1.1.7, as well as the
D614G variant, exhibited similar efficiencies of cell-to-cell transmission compared with the WT (Fig. 7). Moreover, although B.1.351
is more resistant to vaccinee sera in cell-free infection, consistent
with some recent reports (67, 68), B.1.1.7 seems more resistant to
the vaccinee sera for the cell-to-cell transmission route (Fig. 7).
This may explain why B.1.1.7 has a longer duration of acute
infection than other variants (82). The mechanism underlying
these observations is currently unclear, but may have implications for understanding the rapid spread of VOCs in the human
population as well as their increased pathogenesis. The cell-free
route is directly linked to the ability of viruses to infect target
cells and result in spreading among humans through person-toperson contact. In contrast, cell-to-cell transmission has dominant roles in viral pathogenesis and disease progression (24).
Thus, our results on the resistance of B.1.1.7 and B.1.351 to vaccinee sera–mediated inhibition of cell-to-cell transmission and
cell-free infection may provide molecular and virological underpinnings for the prolonged viral replication and rapid spread of
these two variants in the world population (67, 68, 83, 84).
Materials and Methods
Cell culture, virus, constructs, antibodies, and reagents, cell–cell fusion, plaque
assay, ﬂow cytometry, Western blotting, neutralization assay, and statistical
analysis are described in SI Appendix, SI Materials and Methods.
Cell-to-Cell Transmission. In the lentiviral vector system, the expression of
anti-sense reporter gene Gluc is interrupted by an intron oriented in the
sense direction of the HIV-1 genome so that Gluc production will only
occur in infected target cells and not virus producer cells (46). By coculturing the virus producer and target cells, cell-to-cell transmission was determined by measuring the Gluc activity of the cocultured media between
donor cells (such as 293T) producing lentiviral pseudotypes and target cells
(such as 293T/ACE2). Speciﬁcally, 293T cells were seeded in 6-well plates
and transfected with 1.4 μg NL4.3-inGluc and 0.7 μg of plasmids encoding
SARS-CoV or SARS-CoV-2 spike. The next day, transfected 293T donor cells
were digested with phosphate-buffered saline (PBS)/5 mM ethylenediaminetetraacetic acid (EDTA) and thoroughly washed with PBS to remove
EDTA, followed by coculturing with target cells (293T/ACE2, Caco-2, Calu-3,
NCI-H520, or PBMCs) at a 1:1 ratio in 24-well plates for ∼24 to 72 h. Inhibitors
or sera were added as needed. Supernatants were collected and measured
for the Gluc activity.
For examining the cell-to-cell spread of authentic SARS-CoV-2 WT and
VOCs, we infected the donor Vero-ACE2 cells with an MOI of 0.2 (WT) or 0.02
(VOCs) for 20 h and cocultured them with the same number of Vero-mTomatoRed cells for an additional 6 h, in the presence or absence of vaccinee sera. For
the other purposes, Vero-ACE2-TMPRSS2-mTomato cells served as donor cells,
which were infected with WT SARS-CoV-2 (USA-WA1/2020, MOI = 0.01) for
18 h, followed by being cocultured with Vero-ACE2-TMPRSS2, NCI-H520, or
Calu-3 cells under speciﬁc conditions (see legends). Cells were then ﬁxed
with 3.7% formaldehyde for 1 h, followed by washing three times with PBS
before being taken out of the BSL3 laboratory. The ﬁxed cells were incubated
with anti–SARS-CoV-2 nucleocapsid and anti-mouse-FITC, and subjected to
ﬂow cytometry analysis.
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Cell-Free Infection. Cell-free infection was performed along with cell-to-cell
transmission in this work. Brieﬂy, an equal number of transfected donor cells
were seeded in new 24-well plates and maintained for the same period of
time as in cell-to-cell transmission (normally 48 to 72 h). The total volumes
of supernatants were collected and used to infect target cells, which were
seeded with the presence of the same amount of untransfected 293T cells;
this would ensure that the total numbers of cells and density used for cellto-cell and cell-free infection assays were comparable. For the Transwell
setting, the transfected donor cells were seeded onto the insert while target cells, which again were mixed with the same amount of untransfected
293T cells, were on the bottom; this would avoid the contact between donor
and target cells yet the virus can spread through the ﬁlter. Supernatants
were collected at the same time points as cell-to-cell transmission and measured for Gluc activity.

Data Availability. All study data has been deposited into the National Cancer
Institute SeroNet website (https://www.immport.org/shared/study/SDY1890). The
data will go live in January 2022 and it will be available upon request until then.
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